Travere Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Travere Therapeutics

01/08/2024 23:30

* Travere Therapeutics Inc  TVTX.OQ  reported a quarterly
adjusted
loss of 91 cents​​ per share for the quarter ended in June,
higher than the same quarter last year, when the company
reported EPS of $-1.13.  The mean expectation of
fifteen analysts for the quarter was for a loss of 86 cents per
share. Wall Street expected results to range from $-1.06 to -64
cents per share.
    * Revenue fell 9.3% to $54.12 million from a year ago;
analysts
expected $50.17 million. 
    * Travere Therapeutics Inc's reported EPS for the quarter
was a
loss of 91 cents​.
    * The company reported a quarterly loss of $70.41 million.
    * Travere Therapeutics Inc shares had risen by 16.1% this
quarter and gained 6.1% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 7.5%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Travere
Therapeutics Inc is $14.50 
This summary was machine generated from LSEG data August 1 at
10:30 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.86          -0.91          Missed
 Mar. 31 2024      -0.99          -1.76          Missed
 Dec. 31 2023      -1.27                         
 Sep. 30 2023      -0.14